Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vistagen Therapeutics, Inc. (VTGN)

Vistagen cuts about 31% of workforce to focus on fasedienol Phase 3 program

Mixed Impact 3 of 5 restructuring Written later

Vistagen Therapeutics implemented a Board-approved workforce reduction of about 31% on October 26, 2026, keeping staff needed for the U.S. Phase 3 development of fasedienol for social anxiety disorder. The company expects severance and termination costs of about $1.0 million and annual salary and benefit savings of about $3.2 million, and it may incur additional costs not yet contemplated.

Key points

  • Workforce reduced by approximately 31%, implemented October 26, 2026
  • Estimated severance and termination costs of approximately $1.0 million
  • Expected annual salary and benefits savings of approximately $3.2 million
  • Retained capabilities support fasedienol Phase 3 and Phase 2 programs for itruvone and refisolone

The filing

CompanyVistagen Therapeutics, Inc. (VTGN)
Form8-K, current report
Filed with the SECOct 30, 2026, 5:24 PM ET
Accession number0001628280-26-068627

Items reported: 2.05 Exit / Restructuring Costs8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.